Loading
A phase 2 trial of Iruplinalkib in Non-small-cell lung cancer, run by Qilu Pharmaceutical Co., Ltd., with a status the registry has not verified recently.
A Study Evaluates the Safety and Efficacy of WX-0593 in ALK -Positive, or ROS1-positive Non-small Cell Lung Cancer is a phase 2 interventional study registered as NCT04641754 by Qilu Pharmaceutical Co., Ltd., with 176 participants planned, started 2019-03-07 and due to reach its primary completion in 2020-12. Interventions recorded: WX-0593 Tablets. Conditions recorded: Non-small Cell Lung Cancer.
Linked to the drug Iruplinalkib because the registry names it among its interventions and Non-small-cell lung cancer among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Iruplinalkib, ROS1-positive non-small-cell lung cancer, ALK-positive non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Iruplinalkib, Qilu Pharmaceutical, ALK-positive non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares ALK-positive non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares ROS1-positive non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Qilu Pharmaceutical and the tag pipeline.
Shares ROS1-positive non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Qilu Pharmaceutical and the tag pipeline.
Shares ROS1-positive non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/